NCT04387045 is a NA clinical trial of Guilty feelings in Diabetes Mellitus, Type 2, sponsored by Francisco Carlos López Marquez.

Who is sponsoring NCT04387045?

NCT04387045 is sponsored by Francisco Carlos López Marquez.

What drugs are being tested in NCT04387045?

Interventions in NCT04387045: Guilty feelings.

What condition does NCT04387045 study?

NCT04387045 studies Diabetes Mellitus, Type 2.

Is NCT04387045 still recruiting?

NCT04387045 is currently completed. Last updated 15 May 2020.

Last reviewed 2020-05-15 · How we verify

NCT04387045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perceived Stress and Negative Thoughts With Biomarkers in People With Type 2 Diabetes Mellitus and Healthy Subjects

Completed NA Last updated 15 May 2020

What this trial tests

NA trial testing Guilty feelings in Diabetes Mellitus, Type 2 in 40 participants. Completed in 25 August 2017.

Timeline

2 May 2017

Primary endpoint
25 August 2017

25 August 2017

Quick facts

Lead sponsor	Francisco Carlos López Marquez
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	40
Start date	2 May 2017
Primary completion	25 August 2017
Estimated completion	25 August 2017
Sites	1 location across Mexico

Drugs / interventions tested

Guilty feelings

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Francisco Carlos López Marquez

Who can join

Adults 30 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the effect of measured and induced negative feelings on glucose, tumor necrosis factor alpha, and cortisol levels in healthy participants and participants with type 2 diabetes mellitus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04387045 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Francisco Carlos López Marquez
Last refreshed: 15 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04387045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing